Navidea getting new revenue source as cancer diagnostic aid launches in Europe


Story excerpt provided by Columbus Business First.

Written by Carrie Ghose.

Navidea Biopharmaceuticals Inc. gets a new source of sales revenue with the European launch of the drug for which it sold North American rights in spring.

SpePharm AG, a specialty pharmaceutical arm of Dutch distributor Norgine BV, started sales of Lymphoseek in the United Kingdom, Denmark and the Netherlands. SpePharm’s exclusive sub-license applies to all 28 current EU member countries, and it is working to start sales in the rest.

Click here to read the complete article.

Originally published June 12, 2017.

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.

%d bloggers like this: